AI Article Synopsis
- The study investigates intrinsic molecular subtypes of male breast cancer (MBC) and their relationship with clinical and pathological features.
- Out of 130 MBC cases analyzed, the majority were luminal A (45.4%) and luminal B (44.6%), with a smaller percentage being HER2 positive (5%) and triple negative (5%).
- Results indicate significant differences in tumor characteristics based on subtype, but the prognostic value of these subtypes appears to differ from that in female breast cancer.
Article Abstract
Purpose: Intrinsic molecular subtyping has been widely used in female breast cancer, and it has proven its significance. In this article, we aimed to study the intrinsic subtypes of male breast cancer (MBC) in correlation with clinicopathological features.
Methods: We retrospectively identified 130 MBC cases from 2004 to 2013. Intrinsic molecular subtypes were determined by immunohistochemistry (IHC).
Results: From a total of 130 MBC cases, 45.4% of tumors were luminal A subtype, 44.6% were luminal B, 5% were HER2 positive and 5% were triple negative tumors. There were statistically significant differences between different IHC intrinsic subtypes regarding tumor size (p=0.001), estrogen receptor (ER) status (p=0.001), progesterone receptor (PR) status (p=0.001), HER2 status (p=0.001) and Ki67 proliferation index (p=0.001).
Conclusion: The distribution of breast cancer intrinsic subtypes in males is different compared to its female counterpart; however, they don't seem to give the same prognostic value.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!